In the study of Saylor et al., patients with PCa who received ADT for 12 months had lower levels of interleukin (IL)-6 and higher levels of IL-1α and stromal cell-derived factor (SDF)-1α than those who did not receive ADT. This evidence concerns the gene IL1A and posterior cortical atrophy.